<?xml version="1.0" encoding="UTF-8"?>
<p>In another previously reported phase I clinical trial, subjects vaccinated with two doses of an unadjuvanted H7N9 VLP vaccine responded poorly (15.6% seroconversion rates with 45 μg HA dose). In contrast, 80.6% of subjects receiving H7N9 VLP vaccine (5μg HA) with ISCOMATRIX adjuvant developed HAI responses [
 <xref rid="B80-viruses-12-00518" ref-type="bibr">80</xref>]. The results suggest that adjuvants can be important component for the development of safe and effective H7N9 human vaccines [
 <xref rid="B81-viruses-12-00518" ref-type="bibr">81</xref>].
</p>
